Glucose B. Braun Melsunge (Glucose Monohydrate)

Glucose B. Braun Melsunge is an intravenous solution for injection that contains glucose monohydrate as its active ingredient. It is supplied as a sterile liquid formulation intended for infusion, providing a source of carbohydrate energy. The product is manufactured in the European Union and is used in clinical settings where rapid glucose delivery is required.

Glucose B. Braun Melsunge is employed in a variety of medical situations where intravenous carbohydrate supplementation is needed. It supports patients who cannot obtain adequate nutrition orally or enterally.

- Treatment of hypoglycemia when oral glucose is not feasible. - Provision of calories during peri‑operative fasting. - Maintenance of blood glucose levels in critically ill patients. - Dilution and carrier for certain intravenous medications. - Support for patients receiving parenteral nutrition.

Glucose B. Braun Melsunge may cause a range of reactions, most of which are related to the rapid infusion of a carbohydrate solution.

Common: - Mild hyperglycemia that resolves with monitoring. - Transient nausea or vomiting during infusion. - Local irritation or redness at the infusion site.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Allergic reaction such as urticaria, rash, or anaphylaxis. - Electrolyte imbalance, particularly hyponatremia, due to large fluid volumes.

When using Glucose B. Braun Melsunge, clinicians should consider several safety factors to minimize risk. Proper assessment and monitoring are essential.

- Verify patient’s blood glucose level before and during infusion. - Adjust infusion rate in patients with diabetes or impaired glucose tolerance. - Monitor fluid balance to avoid overload, especially in heart‑failure patients. - Use aseptic technique to prevent contamination of the solution. - Assess for signs of allergic reaction during the first administration. - Consider electrolyte status, particularly sodium and potassium, before large‑volume infusion.

Glucose B. Braun Melsunge can influence the effects of other medications and should be administered with awareness of potential interactions.

Avoid: - Concurrent use of high‑dose insulin without appropriate glucose monitoring. - Co‑administration with medications that cause hypoglycemia, such as sulfonylureas, without dose adjustment.

Use with caution: - Beta‑blockers, which may mask hypoglycemia symptoms. - Diuretics that affect electrolyte balance. - Corticosteroids, which can increase blood glucose levels. - Certain cardiac drugs that may be sensitive to fluid shifts.